Doc is proving too much by arguing that a CDR-G score of 0.5 doesn't really fit within the criteria of the draft FDA guidance for stages 1 to 3, because it leaves no situation in which the CDR-G scale can be used by the draft FDA guidance. Why would the FDA even bother to propose to change course in endpoints if, in practice, it couldn't be reasonably applied?
Market Data 
Markets 
AI
